With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.219823-47-9,(R)-Tetrahydrofuran-3-yl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.
Intermediate 84-Bromo-1 -[(SHetrahvdro-furan-3-nuPi-Iota H-pyridin-2-one; A mixture of 4-bromo-1 H-pyridin-2-one (0.50 g), (/:?)-toluene-4-sulfonic acid tetrahydrofuran-3- yl ester (0.40 g), potassium carbonate (0.80 g), and dimethylsulfoxide (5 mL) was stirred at 80 ‘C overnight. After cooling to ambient temperature, water was added and the resulting mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgS04), and concentrated. The residue was purified by HPLC on reversed phase (acetonitrile/water) to afford the title compound [besides, 4-bromo-2-[(S)-tetrahydro- furan-3-yloxy]-pyridine was isolated in 0.36 g (56% of theory)]. Yield: 0.1 1 g (1 6% of theory); LC (method 3): tR = 2.18 min; Mass spectrum (ESI+): m/z = 244/246 (Br) [M+H]+.
219823-47-9, As the paragraph descriping shows that 219823-47-9 is playing an increasingly important role.
Reference£º
Patent; VITAE PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; LEFTHERIS, Katerina; ZHUANG, Linghang; TICE, Colin, M.; SINGH, Suresh, B.; YE, Yuanjie; XU, Zhenrong; HIMMELSBACH, Frank; ECKHARDT, Matthias; WO2011/159760; (2011); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem